Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Versarien Plc LSE:VRS London Ordinary Share GB00B8YZTJ80 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -3.50 -6.73% 48.50 1,921,917 16:35:08
Bid Price Offer Price High Price Low Price Open Price
47.00 50.00 54.00 46.00 54.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Industrial Engineering 9.14 -2.83 -1.64 82
Last Trade Time Trade Type Trade Size Trade Price Currency
16:29:58 AT 5,885 50.00 GBX

Versarien (VRS) Latest News

More Versarien News
Versarien Takeover Rumours

Versarien (VRS) Discussions and Chat

Versarien Forums and Chat

Date Time Title Posts
09/4/202000:01The world lead in real Graphene (nanene) UNCENSORED, yes you can speak freely5,235
08/4/202021:52VRS The world lead in real Graphene (Nanene)100,503
20/3/202013:41I've had enough8
01/2/202018:18No support-
14/1/202019:03The lol thread56

Add a New Thread

Versarien (VRS) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-04-08 15:29:5850.005,8852,942.50AT
2020-04-08 15:29:5047.0020.94AT
2020-04-08 15:29:2648.802210.74O
2020-04-08 15:28:3848.9536,00017,622.00O
2020-04-08 15:23:4247.3018,2508,631.34O
View all Versarien trades in real-time

Versarien (VRS) Top Chat Posts

DateSubject
08/4/2020
09:20
Versarien Daily Update: Versarien Plc is listed in the Industrial Engineering sector of the London Stock Exchange with ticker VRS. The last closing price for Versarien was 52p.
Versarien Plc has a 4 week average price of 22p and a 12 week average price of 22p.
The 1 year high share price is 144p while the 1 year low share price is currently 22p.
There are currently 169,682,290 shares in issue and the average daily traded volume is 1,039,621 shares. The market capitalisation of Versarien Plc is £82,295,910.65.
07/4/2020
14:03
brassneck2: Shavian, I agree with you. It had been implied that Gnanomat tech was still a couple of years away from commercialisation so I very much doubt any big reveal in the next few weeks on something suddenly appearing in production. Mind you Mercedes were recently saying their battery breakthrough was 15 years away so a couple would be quick by that measure. On the share price I think we're unlikely to see day to day progress until there is a commercial deal and substantial order announced. News will drive the VRS share price. Haydale have released a small commercial deal for 2021 and their share price has moved 25-30%. I expect the same for VRS, step changes rather than a smooth line. Hopefully positive news isn't far away on either China, O&G or textiles. I'm sure any of these would give a 20%+ appreciation in share price.
06/4/2020
18:18
holidayfunds8: My feelings on the Lanstead and China JV deals are as follows: * a clever combination of deals – VRS needs short-term funding, and having the Lanstead deal in place strengthens the VRS ‘what price?’ negotiations on the China side; * Also, perhaps an obvious point – but still very important – VRS team knew that these 2 deals would serve to significantly increase the VRS share price; * And this is why the Lanstead instalments do not start immediately – rather, they will start I think in June, or possibly May (RNS says 2 months after), so that the 20day calculation works off these higher share price levels; * And VRS will get £230k per month at a share price of 53.33, increasing by more than 50% to £352k per month if the share price was to increase to, say, 80 pence; see China points below; * On the proposed China buying VRS shares, the RNS stresses that we are looking at 3 EQUAL tranches of shares – up to a maximum 15% VRS shareholding - to occur over the next 15 months (to June 2021) and – this is the critical point – the first of those VRS investments must happen in the next few weeks, before 30June 2020; this is a very short timeframe, so short that – to my mind at least – it points to things being already at an advanced stage of readiness; Now, consider how things look from the viewpoint of our potential China investors: * Behind the scenes, China insiders will now have a good idea of how many new China JV ‘collaborations’ will likely be confirmed over, say, the next 6-9 months; * And those China insiders will have a good idea what impact confirmation of those ‘collaborations’ will have on the VRS share price, with some view of how those arrangements may then translate into commercial, revenue-generating deals for the China JV; * IF those partners calculate that the China JV-related deals will trigger an upward surge in the VRS share price, THEN they will want the 3 tranches of investment in VRS shares to happen pdq; it is not immediately clear to me from the RNS how close in time each of the 3 tranches can be but, IF I held a view that the VRS share price was going to shoot up as a result of my own actions, then I’d want to secure 15% of the company as fast as possible, because if I wait until June 2021, I would generally expect to have to pay more; Anyway, I am now hoping we may see some decent news flow over the coming weeks & months, across multiple fronts: * News that Chinese investors have injected cash, in return for an initial 5% shareholding; * News that the China JV has signed it’s first ‘collaboration’ deals; * And news that – away from China – that VRS has signed a - materially-significant - revenue-generating deal with somebody; Good luck to all current holders, and a massive thanks to those posters who have done the research here.
06/4/2020
07:04
chumbo1: RNS Number : 8113IVersarien PLC06 April 2020 6 April 2020Versarien plc("Versarien", the "Company" or the "Group")Clarification relating to the Lanstead Sharing Agreement and further information on the China joint ventureVersarien plc (AIM: VRS), the advanced materials engineering group, is, pleased to provide further examples, following press comment, in respect of the subscription and sharing agreement with Lanstead Capital Investors LP, announced on 23 March 2020 and re-iterate the terms thereof (the "Lanstead Announcement") in order to aid shareholders understanding and further information on the China joint venture.Terms defined in the Lanstead Announcement are used throughout this announcement, unless otherwise advised. No new information is contained in this announcement other than the table below with examples of proceeds receivable pursuant to the Share Agreement at different prices for the ordinary shares of Versarien based on the Lanstead Subscription price of 40 pence per share (being an approximate premium of 2.5% to the Versarien volume weighted average share price in the 20 days prior to the Lanstead Announcement), and the issue price of the Value Payment Shares issued to Lanstead.Following receipt by the Company of £6 million of gross funds from the Subscription, all of the proceeds were pledged to the Sharing Agreement. Accordingly, and as previously stated, the proceeds of the Subscription were only available for use by the Company for entering into the Sharing Agreement. Consequently, the Company will receive cash settlements from Lanstead over a period of 24 months, commencing in approximately two months, and the amount of proceeds to be received is wholly dependent on the share price performance of the ordinary shares of Versarien each month over the term of the Sharing Agreement.As outlined in the Lanstead Announcement, shareholders should note that the Company also issued to Lanstead 750,000 Value Payment Shares as consideration for entering into the Sharing Agreement, such shares having been issued at a price of 40 pence per share.The Sharing Agreement provides that the Company will receive 24 monthly settlement amounts as measured against a benchmark share price of 53.33 pence per Subscription Share, a premium of approximately 33.33%. Notwithstanding the Subscription Price of 40 pence, shareholders should note that the share price of the Company needs to be on average over the 24 months of the Sharing Agreement at or above the Benchmark Price of 53.33 pence per share for the Company to receive at least, or more, than the gross Subscription proceeds of £6 million.If the Measured Price, calculated as the volume weighted average share price of the Company's ordinary shares over a period of 20 trading days prior to the monthly settlement date, exceeds the Benchmark Price, the Company will receive more than 100 per cent. of that monthly settlement due on a pro rata basis according to the excess of the Measured Price over the Benchmark Price. Should the Measured Price be below the Benchmark Price, the Company will receive less than 100 per cent. of the monthly settlement calculated on a pro rata basis and the Company will not be entitled to receive the shortfall at any later date.For example, if on a monthly settlement date the calculated Measured Price exceeds the Benchmark Price by 10 per cent., the settlement on that monthly settlement date will be 110 per cent. of the amount due from Lanstead on that date. If on the monthly settlement date the calculated Measured Price is below the Benchmark Price by 10 per cent., the settlement on the monthly settlement date will be 90 per cent. of the amount due on that date. Each settlement as so calculated will be in final settlement of Lanstead's obligation on that settlement date.Assuming the Measured Price equals the average Benchmark Price on the date of each and every monthly settlement, Versarien would receive aggregate proceeds of £6 million (before expenses) from the Subscription and Sharing Agreement. If the Measured Price is less than the Benchmark Price on the date of each and every monthly settlement, Versarien would receive aggregate proceeds of less than £6 million (before expenses). If the Measured Price is more than the Benchmark Price on the date of each and every monthly settlement, Versarien would receive aggregate proceeds of more than £6 million (before expenses).In order for shareholders to further understand the possible outcomes from the Sharing Agreement, the Company is pleased to set out below some examples of the amount of proceeds that it would receive in a monthly settlement from the Sharing Agreement, depending on the 20 day average volume weighted share price of the ordinary shares of Versarien in the period prior to the settlement: Measured Price (20 day volume weighted average share price)Monthly gross proceeds #2Approximate monthly net proceeds after all costs #380 pence£375,000£352,00060 pence£282,000£261,00053.33 pence #1£250,000£230,00040 pence£188,000£170,00020 pence£94,000£78,000#1 the Benchmark Price for the Sharing Agreement#2 being the number of Subscription Shares multiplied by the Subscription Price multiplied by the Measured Price divided by the Benchmark Price (being a premium of 33.33% to the Subscription Price) and divided by 24 settlements#3 assuming this is the average Measured Price over the 24 months of the Sharing Agreement The proceeds receivable by the Company over the 24 month duration of the Sharing Agreement will be net of the cost of £300,000 incurred by the Company in entering into the Sharing Agreement with Lanstead, satisfied by the issue of the Value Payment Shares to Lanstead, approximately £30,000 of other costs incurred by Versarien in connection with the Subscription and Sharing Agreement, together with advisory fees paid to a third party adviser to Versarien of 2.5% of the amounts received under the Sharing Agreement.By way of illustration, if the average Versarien share price over the duration of the Sharing Agreement equates to the Benchmark Share Price (an approximate 5% premium to the closing mid-price of the Versarien shares on 3 April 2020) the gross proceeds received by Versarien from the Sharing Agreement would be £6.0 million and the proceeds net of all costs and fees would be approximately £5.5 million.The Directors believe that the Sharing Agreement provides a number of benefits to Versarien and its shareholders including: the certainty of near term income, albeit the quantum is dependent on the Versarien share price; the opportunity to benefit from positive future share price performance; and that the amount of shares issued are fixed, together with the cost of their issue.Whilst theoretically the Company could have potentially raised a greater sum of money per share issued from a future placing of shares if the share price rises above the Benchmark Price, when compared to the proceeds from the Sharing Agreement, this would be dependent on a number of factors such as the willingness of investors to participate in any placing, the ability to achieve a placing at an appropriate discount and the ability of the Company to limit the costs of any such placing. The Directors believe that the proceeds the Company will receive from the Sharing Agreement with Lanstead significantly outweigh the risks associated with any such theoretical placing, the uncertainty of when such a placing may be possible and the uncertainty of achieving a positive outcome. Further information on China joint venture Versarien is pleased to provide further information in respect of the joint venture agreement with Young-Graphene (Beijing) Technology Company Limited ("YG") announced on 25 March 2020, following press speculation.The Company initially entered into negotiations with the Beijing Institute of Graphene Technology Co. Ltd ("BIGT") in March 2019 and a term sheet was executed with BIGT and announced on 15 April 2019. The Company has worked subsequently in co-operation with both BIGT and the China International Graphene Industry Union ("CIGIU") towards the establishment of a joint venture in China which culminated in the joint venture agreement with YG.Due to BIGT's regulatory obligations, exchange controls in China and the downward movement in the Company's share price since executing the term sheet with BIGT, it became unfeasible for BIGT to invest in Versarien at a price level that would have been acceptable to the Company. YG, with the support of both BIGT and CIGIU was established to facilitate, inter alia, an acceptable investment into the Company.As previously announced, the joint venture with YG is conditional on it procuring that strategic equity investment in Versarien within the time frames disclosed in the announcement of 25 March 2020. Further notifications and updates regarding the joint venture and associated financing will only be made in the event that a development occurs that is sufficiently significant to require a regulatory notification.Further details concerning the joint venture with YG, including the terms and conditions and other risk factors are set out in the Company's 25 March 2020 "China update" announcement.
27/3/2020
10:35
evergreen8: I would be amazed if the wider market has a clue of the implications of our recent news. Much like Microsoft announcing the launch of their operating system and first software to a resounding “so what” from the market but with the significant difference that VRS have 300 of the worlds largest corporations funding the establishment of the manufacturing base to secure VAST quantities of VRS product in the shortest possible time scales that the Chinese demand economy can deliver. Forget western snail paced timescales, China has the capacity to build Seven airports from scratch in one year and two hospitals in a fortnight. The instructions from Beijing have now set in motion the rapid development of their High Quality Few layer Graphene production capability in conjunction with VRS as their 50% partner. The markets rear view mirror will soon recognise retrospectively that they missed the boat once the revenues from the MASSIVE Chinese production volumes start to flow with many investors patting themselves on the back if they manage to get in on VRS below £5. I simply have to look at the likes of Fevertree, a one trick pony selling fizzy water, that rose over just two years to above £36, to realise that VRS with GUARANTEED sales to the entire Chinese MASSIVE MARKET that the VRS share price will soon be record breaking and off the chart. Against this backdrop an share price below £1 has got to be the bargain of the century. Prior to this news things were looking very dark indeed but now the future is brighter than I could have imagined. GLALTH
25/3/2020
15:39
nemo19: In addition to all that's happened today, the Q&A from yesterday are now on Investor Meet website. Well done to the team for publishing so quickly. Q1: How important was this financing for your collaborators to move to full commercial deals? It is important for our Directors, employees, customers and shareholders to know the business is secure through what is unprecedented times. This funding provides financial flexibility during times of uncertainty Q2: Can you provide more colour on how the Lanstead funds are to be used across the group? How much towards working capital vs graphene technologies Vs commercial team scale up? We have a holistic view of finance but it is intended to cover the expenses of the business and to supplement the cash and debt facilities the group has. Q3: In addition to the finance arrangement announced with Lanstead, does the company intend to apply for any of the recently announced government assistance i. e. Interest free loan, as an additonal safeguard in the current difficult economic situation? The details of the loans structure are only just now being released, we will where possible look at any opportunity. However these types of mechanisms if based around existing facilities .E.G EFG are extremely hard to secure. Q4: Was the €300,000 loan paid to Gnanomat as mentioned in feb 25th RNS? Yes Q5: Why raise at this difficult times in the markets? As explained in the presentation which is also available on this platform, the world has changed significantly recently and therefore the board took the decision to act firmly and decisively Q6: Does the agreement with Lanstead have an impact on any potential share deals in China? No Q7: Please can we have any information of relationship with University of Exeter We are a partner in some research programs and have a relationship around some specific areas of interest. Q8: What circumstances have stopped use of primary bid. If it is Covid-19, with webinars, call conferencing etc. what is the constraint? It would not make sense for private investors to take shares at a premium , when shares are available via the market cheaper. We have not ruled out future Primary Bid offers at a suitable time. Q9: As we were told recently a fund raising was not required, what does Lanstead bring to the table apart from funds? It is the nature of the fund raise which is important to the company. Q10: As many collaborations are described at commercial stage eg MAS, what delays are you experiencing? The world is experiencing disruption across all continents and this has an impact for some of our customers. Q11: Is there a clause that prevents landstead from Lending stock eg enabling shorting No, but we don't believe it is in the interests of Lanstead to lend stock, as the deal gets better the higher the share price. Q12: Is this a Death Spiral financing agreement? No because the number of shares is fixed at 15,750,000; schemes labelled 'Death Spiral' normally have a fixed amount of cash to be paid every month and a variable number of shares to be issued. This makes this scheme fundamentally different to other schemes. Q13: Should, for some unlikely reason, relations between VRS and Lanstead become sour during the 24-month term, how do you assess or calculate the possibilities re Lanstead manipulating the share price to their possible advantage? In order to get the maximum cash for Lanstead this would require the share price to be much higher, the higher the share price the higher their return. Q14: Is there a lock-in of Lanstead shares? No, the scheme wouldn't work with a lock in. Q15: Should a customer deal during the term require significant spend on production equipment/staff that requires further funding, do you see Lansteads 40p price as a marker or a limit in such funding arrangements? No any deal would be on a case by case basis with the share price being just one of the considerations. Q16: What is the minimum price that VRS will get for its shares issued under the financing agreement? There is not a financing agreement. The Company received 40p per share and re-invested the proceeds in a Sharing Agreement. The proceeds from the Sharing Agreement vary according to the share price with no floor or cap. Q17: What will happen if the general stock market is suspended due to Covid-19, and Lanstead are unable to sell shares in VRS? Then that would be a consideration between the 2 parties but Lanstead has access to cash and does not need to sell shares to pay the settlements. Q18: Does the Board have any concerns about the extent of share price control Lanstead possess given their circa 10% holding? No Q19: What protection do VRS shareholders have if Lanstead decide to sell? It is not in the interests of Lanstead to sell until they have reached the maximum return Q20: Are VRS now ready to be able to cope with, say, a TFL order for 1,000 arches, followed by a further order from Network Rail? Yes we have capacity and an adequate supply chain. Q21: How many Arches does VRS think it could supply over, say, the next 12 months? This is market sensitive information and would constitute a forecast and is therefore not permitted under the market rules. Q22: Does VRS have that supply capability themselves? Or will they use a 3rd party to do that work? Currently a number of 3rd parties but we are looking to bring in house as soon as we have justification Q23: All in, assuming a 1000 production run, what would the fully loaded unit cost per 120kg arch be? And what might VRS sell each arch to TFL? This is market sensitive information and would constitute a forecast and is therefore not permitted under the market rules. Q24: What is the go-to-market strategy for the Arch? Being developed following the recruitment of Dan Smith Q25: VRS having limited in-house production capacity, will some of the major collaboration players that have now selected VRS as their graphene technical know-how IP partner offer production capacity local to their supply needs? This is market sensitive information and would constitute a forecast and is therefore not permitted under the market rules. Q26: How is sentiment in China currently? Good Q27: Does a falling share price make it harder for VRS to agree a BIGT deal involving third parties? If not, is a 15% equity deal at £1.40 still feasible? No it doesn't make it harder. Q28: Is VRS in a position to supply graphene enhanced Asphalt and if so, will you be participating in any anticipated Government tender announcements for this work? No this for everyone is at a research level Q29: Are the 2 UK government secondees still working for Versarien? Yes, and working very hard in the CEO's opinion Q30: What is the company's advertising strategy? Developing hTTps://www.investormeetcompany.com/investor/meeting/subscription-agreement-update
24/3/2020
20:30
superg1: From the Lanstead website Why choose Lanstead as a shareholder and why enter into an accompanying Lanstead sharing agreement? Lanstead aims to be a supportive longer-term equity investor; a “stickier̶1; type of institutional investor. Lanstead shares the upside of its investment with the company to incentivize growth and continues to work closely with companies and their advisers. How does Lanstead invest? Lanstead becomes a shareholder in a company by participating in placings either alongside other institutional investors or as a sole placee. How does the Lanstead sharing agreement work? When Lanstead becomes a shareholder, by purchasing shares in a placing, it also enters into a sharing agreement designed to share the upside in company growth based on a benchmark price (BMP). The sharing agreement provides the opportunity for a company to benefit from positive future news flow. Is Lanstead entitled to invest monthly at a fixed discount to the prevailing company share price from month to month? No. Lanstead will be issued and will immediately pay for all the shares it purchases in a placing. The number of shares issued to Lanstead is fixed and does not change. Does Lanstead benefit by the share price being lower than the BMP, rather than going higher than the BMP? No. Lanstead makes more money the higher the share price rises. Through the sharing agreement Lanstead shares the majority of the upside as a company’s share price appreciates. The sharing agreement is an incentive for the company’s management to perform, thereby benefitting all shareholders including Lanstead. The outcome for the company is contractually clear and the value of Lanstead’s investment is greater if the company’s share price is higher. It is important to note that Lanstead shares the majority, but not all of the upside in any future company share price appreciation. The bottom line is that Lanstead makes more money as the share price rises and does not derive any advantage from a decline in the share price. Can Lanstead trade its shares? Lanstead has a demonstrable track record of being a longer-term supportive shareholder to its investee companies. Like any institutional investor, Lanstead only invests in companies where it can see strong potential for share price appreciation. Lanstead is free to buy and sell shares just like any other shareholder and it is required to disclose movements of >1% as a significant disclosable shareholder. Unlike other shareholders, Lanstead has an uncapped commitment through the sharing agreement to remit amounts each month to the company based on the prevailing share price. Therefore, whilst Lanstead may take a profit along the way (like any shareholder) and cover its downside risk on the investment (just like any shareholder), Lanstead also has an incentive (unlike other shareholders) to maintain a significant on-going shareholding because of its uncapped exposure on the amounts due to the company over the 18 months of the sharing agreement as a company’s shares appreciate.
09/3/2020
23:02
holidayfunds8: LoggieBear, The first 'low-point' of the VRS share price happened 4 weeks ago (on Tues 11 Feb). The intra-day low on that day, and also today, were very similar, as were the closing prices. So the VRS share price today was pretty much the same as it was on Tuesday 11 Feb. Now, if you had a neutral bent of mind, you might observe that - against the modest declines that have hit markets over recent days - the VRS share price has held up pretty well, all things considered. During these same 4 weeks, you have posted over 300 posts, an average of over 10 posts per day. I guess that tells it's own story. Anyway, getting back to to the CNCT Arch: * when we last compared notes, I think you were focused only on the likely graphene tonnage for, say, am order of 1000 arches; * but you must now realise that the Arch opportunity actually relates to the knowledge VRS now has built up on this, in that they have spent a while fine-tuning the exact blend of the graphene-enhanced thermoplastic composite which, in total, weighs around 120kg per arch; * and it is a blend that has been formulated for 3D Printing; * so VRS will supply the graphene-reinforced polymer to the 3D Printer, and those printed pieces can then be supplied by VRS to the likes of TfL, and then assembled over the track; Now, the sort of question that SHOULD have been asked at the IG Interview might have been along these lines: * are VRS now ready to be able to cope with, say, a TfL order for 1,000 arches, followed by a further order from Network Rail? * how many Arches does VRS think it COULD supply over, say, the next 12 months? Less than a 1,000, more than a 1,000; * who exactly will prepare the thermoplastic composite / polymer to give to the 3D Printer? Does VRS have that supply capability themselves? Or will they use a 3rd party to do that work? * all in, assuming a 1,000 production run, what would the fully-loaded unit cost per 120kg arch be? And what might VRS sell each arch to TfL for? Now, you will respond that I am (again) counting my chickens a little early, but it's the above kind of analysis that now needs to be completed, JUST IN CASE TfL are as interested in the CNCT Arch as many think they will be. Now, you can't build a solid investment case on just one JUST IN CASE example. But, then again, if you have dozens of such opportunities with partners that are major players in their respective markets, then you might begin to wonder on 2 main fronts: * on the graphene side - how much quality product of the required grade can VRS now scale-up to provide? As I think you also mentioned, it is not clear what scale of demand VRS could now cope with; * but, also of importance, for most of the partnerships - as confirmed pretty clearly in the IG Interview - VRS's business is to a) figure out the optimal grade & weighting of graphene to add into other materials (plastics / polymers, cement, other composite materials) and b) VRS will then supply that 'blended- product' or end-composite product to customers; * Now, I can't see VRS having the 'in-house' capacity to supply all of these graphene-enhanced materials to customers - so how exactly could that / will that work? Now, given the major players that have now selected VRS as their graphene technical know-how IP partner, I guess those major players have given some thought to the above matters, eh? They can't all be idiots, can they? Now, find me a picture of a 3D-Printed lightweight, graphene-enhanced, aircraft seat (ps I can't find one). But if were Airbus or Boeing, that would be one particular item I'd want to urgently explore, since the seats could be tested & certified relatively quickly. Now, VRS may not be a player in that particular market but, then again, I suppose seats might be classed as 'aircraft interior parts'. Interesting days... (relatively, VRS has been my best performer over the last 4 weeks, hey ho) David
06/3/2020
20:10
holidayfunds8: Tweetie Pie, I am guessing you are reasonably numerate, but I think you may need to re-calibrate your measure of 'being so right'. If you want some brownie points for being 'right' about the drop in the share price since last year then, yes, I am happy to award you a whole bucket. However, over the last few weeks, what I see is as follows: * First cycle - the share price moved down to 37pence to buy, and then moved up to 68pence to sell; * Second cycle - the share price moved down (I think) to 36pence (or even 35pence) to buy, and then moved up to 59pence to sell; * Third Cycle - the share price again moved down into the 30s, but yesterday morning (early), you could sell for 56+ pence; * Forth Cycle - down again into the 30s again today to buy, and we will now need to wait to see how the share price performs over the next days / weeks as we now wait for news or just the Full Year results; Now, I would agree that the 'interview' did not really offer any material new news but, hey, I don't think Neil was in any position to spell out any new, hard news, as that must come via an RNS. But clearly, NR and team have some knowledge on how the various 'collaborations' are now progressing. Now, I do not notice you or loggie as buyers of VRS shares when we dip into the 30s, so I'd suggest that maybe you have missed some decent profit opportunities here. If your aim was to move the VRS share price down into the 30s - well, I'd say you done well, and achieved your target. But if you are of the view that the VRS value lies below these recent lows, then I'd suggest you maybe need to consider that you have called things ever so marginally WRONG over the last few weeks. It's where the share price is heading FROM HERE that now matters, not continuously labouring the point that the share price reached 150pence+ last year. We know that part. So give us predictions of what the share price will be, say, at the end of 2020. To get things started, my personal view is that, yes, the wait for meaningful graphene revenues has been incredibly painful, and things have not perhaps kept to the timing outcomes that many had hoped for but, accepting that VRS is a risky punt - and not one for widows or orphans - my bet is that: * we will see 80+pence sometime during this year; * and the ride here will probably continue to be of the roller coaster variety, and my current plan is to load-up heavily in the 30s, but sell those additional shares if / when short-term profit opportunities arise; and keep doing that; At the moment, there seems to be buyers in the 30s, though I'd accept I could be caught out with this trading approach. But my feeling is that the 30s is a great buying opportunity, with a view to offload within a short time frame. Anyway, please predict what you think will happen to the VRS share price from today's starting point, and you will then - if correct - impress all of us. But, as far as I can tell, you been calling this wrong over the past few weeks.
24/2/2020
09:41
ridicule: Nice to see some new posters on board, I do not communicate with the foul mouthed Club Sandwich, but his inane comments are at last beginning to lose their effect. I have not posted very much at all on here in recent months, since this board went completely to rats. I am still a significant holder and the story is still in tact, notwithstanding the timescales have slipped. I would like to make a few points: VRS do not sell, they collaborate to enable other, much bigger players to sell, like AECOM, MAS, Nike, Unilever etc. The selling cycle for this new technology is in the hands of these big players and their end customers in some cases, including their supply chain participants. We are told by VRS that there are no significant extra costs in introducing their high grade graphene into the many processes that some 40+collaborations are involved with. We have been told by VRS that there are 5 major projects that they are concentrating on to commercialise this year. Any one of which, in my view, will get the share price back towards the highs that it reached when the hope element was supported by a much higher level of optimism amongst VRS shareholders than at [present. I am personally content that China is not at the committed stage.I was concerned over IP, the power of China to manipulate and the dangers to the survival of the company if things went wrong in China when any one of the non Chinese collaborations were capable of getting the VRS share price back to the high watermark. I had these thoughts of course before COVID 19. I have read a number of criticisms over the failure to recruit a CTO and the poor salary on offer. I recollect conversations with Neill Ricketts and Chris where the CTO role was intended to start looking at ways to exploit the other 2D materials: some 2000, Hexotine being the first for VRS. Given the way Nanene and Polygren applications have moved to the right and the current cashposition, I applaud the fact that they have not taken on the overhead of a CTO. Moreover, a VRS based CTO would have little impact on the progress of the existing collaborations, they are being driven by the big player product development departments and the various Catapults that have been set up with Government funding to accelerate the adoption of Graphene. The big prize for us is VRS is the chosen graphene partner, they are seen as the leader at the top end of the graphene range and they have demonstrated the scaleability of output, including the EU reach programme. That is why they are the selected partner in so manycollaborations. Indeed, I have yet to discover another company operating at the high end as they do. The other question that never gets raised on here is. Why have all these major companies across a myriad of Verticals taken the trouble and expense to collaborate? Because they want and believe in a successful outcome. Why else would they do it? One aspect of China is the failure of a 15% stake to appear. This was deemed necessary for the next step up the value chain, through acquisition, and in my view companies like Scaled were in their sights. This is a set back. That said anyone of the 5 targets they are hoping to secure this year will restore the share price and hopefully trigger the second option to the China stake- investment by HNW individuals. The lack of a big order has prevented that option triggering to date. The second setback is the attempted destabilising of NR himself. The remorseless attack by Share Prophets who sensed their oft repeated blood letting opportunity and have savaged him, including the reporting process to the Regulators. Imagine how we would feel under such attack? Trying to grow an exciting company, introducing an untried technology while trying to hold a share price, not for personal gain, but to maintain a level that made a 15% stake build viable. Caroline Flack took her life under such pressures. I am not suggestung NR is remotely at that stage, but it has caused a wobble - Discord and the imposed silence. What really angers me is that some are almost salivating over these developments, when they should be supporting a fantastic British company on the threshold of delivering for our post-BREXIT UK the materials element of the 4th Industrial revolution. I will not be responding to the anticipated vitriol from the detractors.
21/2/2020
13:21
rogerthegrouch: "The world builds or renovates lots of railways + VRS have put some of their graphene in a product being tested by one of AECOMs subcontractors and they've released some PR on it => VRS share prices is going to the moon." Not quite but a good try. Your equation is correct if you add in a load of other stuff like textiles, concrete, aero parts etc. If only we had those too it would be a sure thing, oh wait we DO have those things and a whole lot more. Jupiter? I like this too... "Neill he gives them such "mind blowing" forecasts that it blows up their calculators" Another gold star
Versarien share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
VRS
Versarien
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200409 04:58:45